entity

TDP-43 RNA processing / phase separation

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about TDP-43 RNA processing / phase separation: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1Connections
4Hypotheses
1Analyses
0Outgoing
1Incoming
12Experiments
2Debates

No AI portrait yet

Outgoing (0)

TargetRelationTypeStr
No outgoing edges

Incoming (1)

SourceRelationTypeStr
TARDBPparticipates_ingene0.42

Targeting Hypotheses (4)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Cross-Seeding Prevention Strategy 0.689 neurodegeneration RNA binding protein dysregulation across
Glycine-Rich Domain Competitive Inhibition 0.640 neurodegeneration TDP-43 phase separation therapeutics for
TDP-43 Cryptic Exon–Targeted ASOs to Restore Hippocampal Gam 0.577 neurodegeneration RNA binding protein dysregulation across
Cryptic Exon Silencing Restoration 0.531 neurodegeneration RNA binding protein dysregulation across

Mentioning Analyses (1)

Scientific analyses that reference this entity

TDP-43 phase separation therapeutics for ALS-FTD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.738

Experiments (12)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
TDP-43 mutant mouse model cGAS/STING pathway analysis validation amyotrophic lateral sclerosis 0.900 0.00 TDP-43 mutant mice proposed N/A
TDP-43 mitochondrial invasion and DNA release via mPTP exploratory amyotrophic lateral sclerosis 0.900 0.00 cultured cells proposed N/A
TDP-43 mitochondrial invasion and mtDNA release in iPSC motor neurons exploratory Amyotrophic Lateral Sclerosis 0.900 0.00 iPSC-derived motor neurons proposed N/A
cGAS/STING pathway validation in TDP-43 mutant mice validation Amyotrophic Lateral Sclerosis 0.850 0.00 TDP-43 mutant mice proposed N/A
cGAMP biomarker analysis in ALS patient spinal cord samples exploratory Amyotrophic Lateral Sclerosis 0.800 0.00 Human ALS patient spinal cord proposed N/A
TDP-43 pathology prevalence and distribution in AD cases exploratory Alzheimer's disease 0.800 0.00 human postmortem brain tissue proposed N/A
Cognitive impact of TDP-43 pathology in AD patients clinical Alzheimer's disease 0.700 0.00 human patients completed N/A
Proposed experiment from debate on TDP-43 undergoes liquid-liquid phas falsification Neurodegeneration 0.400 0.50 cell_line proposed $80,000
s:** - Single-cell RNA-seq to measure editing efficiency across differ falsification ALS 0.400 0.50 cell_line proposed $150,000
Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for P clinical Parkinson's Disease 0.400 0.50 human proposed $5,460,000
ALS Progression Rate Heterogeneity — mechanism and biomarker predictor clinical ALS 0.400 0.50 human proposed $6,550,000
s:** - Temporal analysis showing mitochondrial defects precede other p falsification Neurodegeneration 0.400 0.50 cell_line proposed $80,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Autophagy and ALS: mechanistic insights and therapeutic implications. [PMID:34057020] Chua JP, De Calbiac H, Kabashi E, Barmad Autophagy 2022 2
TDP-43 Pathology in Alzheimer's Disease. [PMID:34930382] Meneses A, Koga S, O'Leary J, Dickson DW Mol Neurodegener 2021 2
Protein transmission in neurodegenerative disease. [PMID:32203399] Peng C, Trojanowski JQ, Lee VM Nat Rev Neurol 2020 2
TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS [PMID:33031745] Yu CH, Davidson S, Harapas CR, Hilton JB Cell 2020 2
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of [PMID:30335591] Rusmini P, Cortese K, Crippa V, Cristofa Autophagy 2019 2
Targets and Gene Therapy of ALS (Part 1). [PMID:40362304] Shiryaeva O, Tolochko C, Alekseeva T, Dy Int J Mol Sci 2025 1
The genetics of amyotrophic lateral sclerosis. [PMID:38967083] Nijs M, Van Damme P Curr Opin Neurol 2024 1
TDP-43 regulates LC3ylation in neural tissue through ATG4B cryptic splicing inhi [PMID:39305312] Torres P, Rico-Rios S, Ceron-Codorniu M, Acta Neuropathol 2024 1
N protein of PEDV plays chess game with host proteins by selective autophagy. [PMID:36861818] Zhai X, Kong N, Zhang Y, Song Y, Qin W, Autophagy 2023 1
PIKFYVE inhibition mitigates disease in models of diverse forms of ALS. [PMID:36754049] Hung ST, Linares GR, Chang WH, Eoh Y, Kr Cell 2023 1
TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. [PMID:35197628] Brown AL, Wilkins OG, Keuss MJ, Kargbo-H Nature 2022 1
Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP- [PMID:28405022] Becker LA, Huang B, Bieri G, Ma R, Knowl Nature 2017 1
Selective Silencing of TDP-43 P. G376D Mutation Reverses Key Amyotrophic Lateral [PMID:41897327] Romano R, Ruotolo G, Perrone F, Tomasell Biomolecules 2026 0
ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies. [PMID:41570741] Genin EC, Paquis-Flucklinger V Current opinion in neurobiolog 2026 0
Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Protein [PMID:41900026] Jamerlan A, Hulme J Molecules (Basel, Switzerland) 2026 0
Axonal transport impairment as an upstream mechanism in amyotrophic lateral scle [PMID:41890591] Gabbay U Frontiers in neuroscience 2026 0
Defining RNA oligonucleotides that reverse deleterious phase transitions of RNA- [PMID:41512823] ["Guo L", "Mann J", "Mauna J", "Copley K Molecular cell 2026 0
Role of Alpha-Synuclein in Frontotemporal Dementia: Narrative Review. [PMID:41827903] Bougea A Cells 2026 0
Versatile CRISPR-Cas Tools for Gene Regulation in Zebrafish via an Enhanced Q Bi [PMID:41671402] ["Shi M", "Ge W", "Li C", "Liu B", "Deng Advanced science (Weinheim, Ba 2026 0
Splicing the narrative: alternative TARDBP splicing and its relation to neurodeg [PMID:41837283] Miller MR, Dykstra M, Barmada S The Journal of clinical invest 2026 0

Debates (2)

Multi-agent debates referencing this entity

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small

closed · Rounds: 6 · Score: 0.84 · 2026-04-12

TDP-43 phase separation therapeutics for ALS-FTD

closed · Rounds: 4 · Score: 0.95 · 2026-04-11

Related Research

Hypotheses and analyses mentioning TDP-43 RNA processing / phase separation in their description or question text

No additional research found